Allergy Therapeutics (LON:AGY) Sets New 12-Month Low – Here’s What Happened

Allergy Therapeutics plc (LON:AGY) shares hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as GBX 6.50 and last traded at GBX 7.50, with a volume of 203060 shares changing hands. The stock had previously closed at GBX 7.50.

Allergy Therapeutics Stock Performance

The company has a quick ratio of 1.48, a current ratio of 1.13 and a debt-to-equity ratio of 629.58. The stock has a market capitalization of £474.94 million, a P/E ratio of -7.73, a PEG ratio of -30.70 and a beta of 0.89. The firm’s 50-day simple moving average is GBX 9.75 and its 200 day simple moving average is GBX 10.56.

Allergy Therapeutics (LON:AGY) last posted its quarterly earnings data on Tuesday, March 31st. The company reported GBX (0.38) earnings per share (EPS) for the quarter. Allergy Therapeutics had a positive return on equity of 409.00% and a negative net margin of 85.46%.The company had revenue of GBX 3,628 million for the quarter. Equities research analysts anticipate that Allergy Therapeutics plc will post -2.56 EPS for the current fiscal year.

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.